Sanofi - American Depositary Shares (SNY)

Regeneron's biggest growth driver still has plenty of fuel left in the tank.

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event. Quigley said Chief Executive Offic

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) ( Profile ) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at protecting and potentially repairing the myelin sheath itself. The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. This momentum places Quantum BioPharma solidly in a group of leading companies focused on the treatment of serious diseases and areas of significant unmet medical need across vaccines, ophthalmology and neurological disease, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and…

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) (profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at protecting and potentially repairing the myelin sheath itself. The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. This momentum places Quantum BioPharma solidly in a group of leading companies focused on the treatment of serious diseases and areas of significant unmet medical need across vaccines, ophthalmology and neurological disease, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN).

They could both outperform the market over the medium term, but one appears to have a clear edge.

The company has increased its dividend for 30 consecutive years.

Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongo

Add the effect of stock buybacks to the dividend, and you're looking at a total yield approaching 11%.

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

All three can be bought on the dip.

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

These stocks pay between 5.3% and 6.7% in dividends.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.